Saeed Tavazoie

NextBio Corp. provides a scientific platform to aggregate and interpret quantities of genomic data for research and clinical applications. It offers products for pharmaceutical, bio-tech, academia, and medicine organizations. The company was founded by Saeid Akhtari and Ilya Kupershmidt in 2004 and is headquartered in San Diego, CA.

Redwood Bioscience Inc. develops precision protein-chemical engineering technology to produce the next-generation of antibody-drug conjugates and other semi-synthetic biotherapeutics. It employs natural post translational modifications found in human cells to site specifically create one or more aldehyde tags on protein molecules, including monoclonal antibodies. The firm's platform is enabled with precision chemistries, payload positioning and defined stoichiometry of payload protein ratios. The company was founded by Carolyn R. Bertozzi, Mike Blank and David Rabuka in 2008 and is headquartered in Emeryville, CA.

GSK Equity Investment Ltd (GSK Equity) is a venture capital firm a subsidiary of GlaxoSmithKline Plc founded in 1985. The firm is headquartered in Reedwood City, California.

Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA.

Pomona College offers curriculum in the arts, humanities, social sciences and natural sciences. It was founded in 1887 and it is headquartered in Claremont, CA

Goldman Sachs & Co. LLC (GS&Co.) is a securities brokerage firm headquartered in New York City. Founded in 1927, the firm is a subsidiary of The Goldman Sachs Group, Inc. (NYSE: GS). GS&Co. provides services to help hedge funds manage risk, monitor portfolios, maintain liquidity and build their businesses. They offer clients access to global equity and derivatives markets, as well as foreign exchange, commodities, European Lefts, rates and credit across the Americas, Europe and Asia. The firm proactively monitors capital markets, searching for pockets of liquidity and news that may require changes to those strategies. Integration with the Goldman Sachs network gives clients access to the firm's sectored block trades and their insights into price discovery. Their electronic trading program provides clients with tools to manage their trades from pre-trade analytics to post-trade analysis.

The University of Liverpool operates as a university. It offers post graduate research, foundation courses, continuing and professional development, online study, and doctoral college. The company was founded in 1881 and is headquartered in Liverpool, the United Kingdom.

Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts.

Ethicon, Inc. develops and markets medical products and devices for surgery. It offers different types of services such as wound management, women's health, and cardiovascular surgery. The company was founded by George F. Merson in 1915 and is headquartered in Somerville, NJ.

Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ.

Arresto Biosciences, Inc. is a biotech company that develops medicines to treat cancer and fibrotic diseases by targeting extracellular matrix proteins. The company was founded by Amato Giaccia, Michael T. Longaker and Geoffrey C. Gurtner in 2007 and is headquartered in Palo Alto, California.

Canbex Therapeutics Ltd. engages in the development of novel peripherally-acting cannabinoid agonists and mimetics for the treatment of multiple sclerosis spasticity and pain. Its lead drug candidate, VSN 16, has been established as a potent, stable and orally-available agonist of GPR-55 with a clear anti-spasticity effect in a validated preclinical model. The company was founded by David Baker, Gavin Giovannoni, Cristina Visintin, Gareth Pryce and David Lawrence Selwood in 2005 and is headquartered in London, the United Kingdom.

Ethicon Corp. manufactures and markets surgical sutures. The company is headquartered in Somerville, NJ.

Auxogyn, Inc. provides novel scientific and development biotechnology services. It is focused on advancing the field of reproductive health through its uniquely-combined knowledge of early human developmental biology, advanced computer vision technology and best clinical practices. The firm's first product, the Eeva test, is designed to provide quantitative information regarding embryo development to assist IVF clinicians in optimizing the treatment path for their patients undergoing IVF procedures. The company was founded by Renee A. Reijo Pera, Barry Behr, Thomas Baer, Connie Wong, Lissa A. Goldenstein and Kevin Loewke in 2008 and is headquartered in Menlo Park, CA.

ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field.

Novo Ventures (US), Inc. is a venture capital firm located in San Francisco. The firm is a subsidiary of Novo A/S and their ultimate parent is Novo Nordisk Fonden.

Asceneuron SA operates as a biotechnology company. It develops therapeutics for orphan tauopathis and Alzheimer?s disease. The firm specializes in small molecule drug discovery for neurodegenerative diseases. The company was founded by Dirk Beher, Frank Murdoch Armstrong and Christoph Wiessner in October 2012 and is headquartered in Lausanne, Switzerland.

Amphivena Therapeutics, Inc. provides drug discovery services. It develops tetravalent, T-cell redirecting bispecific antibodies for the treatment of hematologic malignancies. The firm’s’ lead drug candidate is AMV-564, a CD33/CD3-targeting treatment for acute myeloid leukemia (AML), which Amphivena is currently preparing to advance into clinical development. The company was founded by Jeanmarie Guenot in December 2012 and is headquartered in San Francisco, CA.

Pi-Cardia Ltd. develops catheter for the treatment of aortic stenosis. Its technology is based on delivering mechanical impact for creating fractures in valve calcifications, without injuring the surrounding soft tissue. The company was founded by Eyal Kolka and Erez Golan in 2009 and is headquartered in Rehovot, Israel.

Kanyos Bio, Inc. engages in the provision of immune tolerance technology solutions. It develops antigen-specific for treatment of type-1 diabetes and celiac disease. The company was founded by Jeffrey Hubbell, Stephan Kontos, Oscar Buset, Kristen M. Lorentz, and David A. Lowin in 2015 and is headquartered in Cambridge, MA.

Blade Therapeutics, Inc. offers anti-fibrotic therapies to meet unserved patient needs. Its product portfolio is to address various fibrotic diseases and their underlying pathophysiology. The company was founded by Hal Dietz and Wendye R. Robbins and is headquartered in South San Francisco, CA.

Tmunity Therapeutics, Inc. develops novel products that free the immunological potential of T cells to treat disease indications. It develops novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms. The company was founded by Carl H. June, Anne Chew, Bruce Levine, Yangbing Zhao, James L. Riley and Bruce Blazar and is headquartered in Philadelphia, PA.

Civilization Ventures LLC (Civilization Ventures) is a venture capital firm founded in 2016 by Shahram Seyedin-Noor. The firm is headquartered in San Francisco, California.

Comet Therapeutics, Inc. develops and commercializes treatments for patients suffering from metabolic, neurological and immunological disorders. The company was founded by Angellina Sekirnik and Enej Kuscer in 2008 and is headquartered in Cambridge, MA.

Noema Pharma AG is a biotechnology company, which engages in the development of orphan neurological disorder therapies. It focuses on understanding and meeting patient needs using novel therapies. The company was founded by Luigi Costa and George Garibaldi and is headquartered in Basel, Switzerland.

U1 Bio, Inc. provides biotechnology research and development services. The CEO of the American company is David Nelles.

Foresight Diagnostics, Inc. is a privately held cancer diagnostics company based in Aurora, CO. The company has developed a liquid biopsy testing platform for the measurement of minimal residual disease (MRD) that is significantly more sensitive than existing tests, with a detection limit below 0.0001% or one part-per-million. This improved sensitivity provides actionable information to physicians and biopharmaceutical companies to enable more personalized treatment approaches for patients with a variety of cancers. The company's experts specialize in liquid biopsy and cancer genomics, developing an MRD assay centered on the detection of ctdna via phased variant sequencing. The company uses phased-seq® liquid biopsy technology for cancer relapse surveillance by monitoring cfdna/ctdna in the blood of lymphoma and lung cancer patients. The company was founded by Maximilian Diehn, Ash Alizadeh, Jake Chabon, and David Kurtz, with Jake Chabon serving as the CEO since incorporation.

Mnemo Therapeutics SAS is a French biotechnology company that develops cell therapies to create accessible cures for cancer patients. The company is based in Paris, FR, and has subsidiaries in the United States. The company applies a novel approach to cell therapy using its enfinit platform, a groundbreaking drug discovery engine. Mnemo is committed to addressing the challenges in the field of immuno-oncology, such as a lack of cancer-specific targets, long-term persistence, and sensitivity. The company aims to engineer the future of immunotherapies to transform the lives of people with cancer by discovering novel cancer-specific targets and boosting immune activity to treat solid tumors. The company was founded in 2019 by Alain Maïore and Michel Sadelain. Robert LaCaze has been the CEO of the company since 2022.

Home Biosciences SAS is a biotech venture builder that partners with academics and scientists to develop life-changing therapies for patients. The company is based in France and has subsidiaries in the country. The French company's operating model allows its teams to focus on scientific and operational excellence to expedite and de-risk the discovery and development paths of its projects, which are housed in dedicated ventures and fully financed by Home Biosciences. Home Biosciences was founded in 2019 by Magali Richard and David S. Schilansky, who has been the CEO since its inception.

Empyrean Neuroscience is an American genetic engineering company that specializes in developing neuroactive therapeutics to treat neuropsychiatric and neurologic disorders. The company is based in and, but their location is not specified. The company's platform allows for the creation of small molecule therapeutics through precision genetic modification, transformation, and regeneration of fungi and plants. Additionally, their platform enables the discovery of novel small molecules that may exhibit therapeutic properties.

Moon Surgical SAS is a French medical technology company that is creating a new category of robotic surgery. The company is based in Paris, France and is operated by renowned serial medical innovators and backed by leading venture capitalists. Its Maestro system enhances existing laparoscopic techniques and tools with new capabilities, benefiting the 93%% of patients who currently do not have access to minimally invasive robotic surgery. The CEO of the company is Anne Osdoit.

True North Therapeutics, Inc. operates as a biopharmaceutical company. It focuses on the discovery, development, and commercialization of first-in-class product candidates for complement-mediated diseases. The company was founded by Nancy E. Stagliano in 2013 and is headquartered in South San Francisco, CA.